Cerus Intercept trial update
This article was originally published in The Gray Sheet
Executive Summary
FDA's Blood Products Advisory Committee recommended Nov. 16 more stringent safety margins in Cerus' proposed Phase III trial design for its Intercept blood pathogen inactivation system, which might require the company to enroll more patients than expected, according to the firm. Otherwise, the committee agreed with Cerus' proposed hemostatic efficacy and safety endpoints in the planned trial comparing Intercept-treated platelets and conventional platelets used in transfusions. The firm already completed a similar Phase III study for Intercept, enrolling 645 patients, which met its primary endpoint, but FDA had concerns with the trial design. "We now need to conduct further discussions with the FDA to agree upon a final protocol," Cerus CEO Claes Glassell said
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.